All News

Lindsay Tom

Hidden in Plain Sight: IBD

d Lindsay Tom PA-C

As a PA with six years of experience in rheumatology and a background in gastroenterology, today I'm discussing the clinical overlap between inflammatory arthritis—particularly psoriatic arthritis and spondyloarthropathies—and inflammatory bowel disease.

Read Article
AOSD.temp_.jpg

Disease Activity Criteria for Adult-Onset Still's Disease: EULAR Points to Consider

d Jack Cush, MD

EULAR has published a "points to consider" (PtCs) guidance on the development of criteria for the assessment of the disease activity in adult-onset Still’s disease (AOSD).

Read Article
ACR Clean (Keep)

ACR: New Data Highlights Urgent Need to Address Arthritis Burden

d Jack Cush, MD

New findings from national U.S. surveys reveal the profound impact of arthritis on millions of adults, especially those facing social and economic challenges. These data will be featured in an upcoming issue of Arthritis Care & Research, an official journal of the American College of Rheumatology.

Read Article
EULAR.Docs.APP

Role of the Nurse in the Care and Management of Rheumatic Diseases - EULAR Review

d Jack Cush, MD

In 2023, a EULAR subcommittee set out to assess the roles of nurses and Advanced Practice Nurses (APN) in the care of arthritis as outlined in published EULAR guidelines. The scope of APN practices was first proposed in 2012 and revised in 2018.

Read Article
ANA APR Cover image

Antinuclear Antibodies (ANA)

d Jack Cush, MD

Dr. Jack Cush reviews autoantibody testing in rheumatology.

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Optimizing Hydroxychloroquine Blood Levels in Lupus

d Jack Cush, MD

A large observational cohort study suggests that monitoring hydroxychloroquine (HCQ) blood levels is effective in systemic lupus erythematosus (SLE) patients with a target therapeutic range (for HCQ level monitoring) of 750-1150 ng/ml.

Read Article
Wolters Kluwer surveyed 203 PAs: - 62% wish for more clinical experience prior to - Most adopted AI, majority need more AI training - 45% prefer title of “physician associate” https://t.co/96Hkh21wSr https://t.co/j7Xep47qMN

Links:

Dr. John Cush RheumNow ( View Tweet)
Japanese retrospective study-194 #RA pts Rx w/ JAK inhib (74 vaccinated w/ recombinant zoster (RZV) & 120 Not-Vax). H.zoster lower w/ RZV (4.8/100PY) vs UnVax (7.8/100PY) w/ overall efficacy of 59.1%. RSV Vax pts who got HZ had signif lower lymphocyte #s, higher SDAI & CDAI. https://t.co/4VMWPhzXeL
Dr. John Cush RheumNow ( View Tweet)
NEW ONLINE ACR POSTER: 2-year efficacy and safety outcomes with a JAKi in patients with GCA Click to see the latest results from a Phase 3 trial presented at ACR 2025, sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/Tm8m43ZXBM https://t.co/bE1ziHy1no

Links:

Dr. John Cush RheumNow ( View Tweet)
French ESTIVAL study - DB, sham trial of auricular vagal N stimulation in 148 Erosive hand OA (eHOA) pts w/ erosion + synovitis by US. @12wks, no signif difference in VAS pain (–16·0 vs –6 sham; p=0·22) w/ no safety issues. Was this a failed study or encouraging outcome? https://t.co/KI86H9izYS
Dr. John Cush RheumNow ( View Tweet)
76 PsA pts asked 32 questions submitted to Chat-GPT4 & 12 specialists. Answers were scored (accuracy, completeness). Both equally accurate, ChatGPT scored lower in completeness. Other pts reviewed answers; they preferred ChatGPT 49% vs clinician 34%. ChatGPT was more readable.

Dr. John Cush RheumNow ( View Tweet)

Study of 177 #SSc pts (116 w/ SSc-ILD vs 61 without ILD). SSc-ILD had more dcSSc, Raynaud’s & GI Dz. SSc-ILD predicted by triad of elevated NLR, PT, anti-SCL-70 (AUC of 0.879; sensitivity 82.6%; specificity 85.0%). NLR: neutrophil to lymphocyte ratio; PT: prolonged prothrombin https://t.co/iI6ZnZgJE7
Dr. John Cush RheumNow ( View Tweet)
Austrian 1K Paracelsus cohort study; from 9,665, 296 (3.1%) had RA. CKD prevalence was higher in RA vs controls (11.8% vs. 6.7%, p<0.001). Albuminuria was dominant renal dz in RA (6.8% vs 4.2%, p=0.027), but missed signif after adjustments (OR 1.43; 0.96–2.13) https://t.co/qf0IpZC50Q
Dr. John Cush RheumNow ( View Tweet)
Reefer Madness (12.12.2025) Dr. Jack Cush reviews the news, journal and regulatory reports from this past week on RheumNow. B cell drugs in SLE and ITP, biomarkers in GCA & PSS and great videos by APPs. https://t.co/SKEYlhTfLz https://t.co/mBX4GIQxKe

Links:

Dr. John Cush RheumNow ( View Tweet)
Evaluation of Rheumatic Complaints https://t.co/cdizOgFqYf https://t.co/sqbrY2oGcH

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumaKnowledgy Card https://t.co/ZPTmT8kgDX https://t.co/E3IREKimx6

Links:

Dr. John Cush RheumNow ( View Tweet)
AANP survey of US 2338 Nurse Practitioners (mostly primary care) re: shared pts w/ rheumatologists. NPs managing RA want improved communication w/ rheums, & education on RA management. PC NP confidence w/ RA was 47% Somewhat confident, 6% very confident, 19% not confident. https://t.co/YVEpJua9hj
Dr. John Cush RheumNow ( View Tweet)
Top 10 States to Practice Rheumatology 1 North Dakota 2 Wisconsin 3 Alaska 4 Montana 5 South Dakota 6 Nebraska 7 Minnesota 8 Washington 9 Utah 10 Maine https://t.co/x2tKflV2S7 https://t.co/fLMEhQV0js

Links:

Dr. John Cush RheumNow ( View Tweet)
Tarsal Tunnel Syndrome - review and quiz. A compressive neuropathy of the posterior tibial nerve within the tarsal tunnel. 80% caused by lipoma, ganglion, varicosity, trauma, tenosynovitis, rheumatoid arthritis, diabetes, etc https://t.co/zCyeVIJEuy https://t.co/f4jA13FDvN

Links:

Dr. John Cush RheumNow ( View Tweet)
In US, Tofacitinib loses patent exclusivity & goes generic in 2026. Worldwide Tofa sales in 2024 were $3.08 billion (55% use in RA; N. America 1st w/ ~38% of market). Tofa sales projected to rise to $5.7 bill in 2029 https://t.co/nKPaQdglYw https://t.co/DdMymmk8go

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×